- ZyVersa Therapeutics (ZVSA, Financial) is advancing its Inflammasome ASC Inhibitor IC 100 with key milestones set for 2025.
- The global anti-inflammatory biologics market is projected to grow from $105 billion in 2024 to $186 billion by 2034.
- IC 100 aims to address chronic inflammatory diseases, initially focusing on obesity-associated cardiometabolic conditions.
ZyVersa Therapeutics, Inc. (ZVSA), a clinical-stage biopharmaceutical company, has issued a shareholder letter highlighting significant progress in the development of its Inflammasome ASC Inhibitor IC 100. The company is targeting chronic inflammatory diseases, with an initial focus on obesity-associated cardiometabolic conditions.
The global market for anti-inflammatory biologics offers substantial opportunities, with projections indicating growth from $105 billion in 2024 to $186 billion by 2034. ZyVersa's development timeline for IC 100 includes several near-term milestones. A proof-of-concept study using a diet-induced obesity mouse model is slated to begin in the first half of 2025, with preliminary results expected by the second half of the same year.
Additionally, ZyVersa plans to submit an Investigational New Drug (IND) application in the second half of 2025, followed by the commencement of a Phase 1 clinical trial targeting overweight subjects with cardiometabolic risk factors. The company anticipates results from this trial in the first half of 2026. A preclinical study for Parkinson's disease, funded by The Michael J. Fox Foundation, has been completed, and a manuscript has been accepted for publication.
IC 100 is distinguished by its unique mechanism of inhibiting ASC and ASC specks, potentially enabling broader inflammasome inhibition and offering superior control over inflammation compared to single-target NLRP3 inhibitors. ZyVersa is also considering expansion into other therapeutic areas, including Parkinson's disease, Alzheimer's disease, and multiple sclerosis.
- CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
- Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
- Double Buys: Companies that both Gurus and Insiders are buying
- Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.
